# Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

> **NCT03807063** · PHASE1 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Acute Bilineal Leukemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Myeloproliferative Neoplasm
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Chronic Myelomonocytic Leukemia
- Recurrent Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** Rivogenlecleucel
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT03807063
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-02
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Insufficient funding
- **Last updated:** 2020-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03807063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03807063, "Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03807063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*